Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 38

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 38
---
 SEC, which are incorporated by reference into this prospectus.

Our business, affairs, prospects,
assets, financial condition, results of operations and cash flows could be materially and adversely affected by these risks. For more
information about our SEC filings, please see “Where You Can Find More Information”.

<div align='center'>5

USE OF PROCEEDS</div>

Unless otherwise indicated in a prospectus supplement,
we intend to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, including to support
research and development, including clinical trials, and general corporate purposes.

<div align='center'>6

DESCRIPTION OF CAPITAL STOCK</div>

General

The following description of our capital stock,
together with any additional information we include in any applicable prospectus supplement or any related free writing prospectus, summarizes
the material terms and provisions of our common stock and the preferred stock that we may offer under this prospectus. While the terms
we have summarized below will apply generally to any future common stock or preferred stock that we may offer, we will describe the particular
terms of any class or series of these securities in more detail in the applicable prospectus supplement. For the complete terms of our
common stock and preferred stock, please refer to our articles of incorporation and our bylaws that are incorporated by reference into
the registration statement of which this prospectus is a part. The summary below and that contained in any applicable prospectus supplement
or any related free writing prospectus are qualified in their entirety by reference to our articles of incorporation and our bylaws.

Common Stock

We are authorized to issue 200,000,000 shares
of common stock, $0.001 par value per share. As of the date of this prospectus, there are 19,760,985 shares of common stock issued
and outstanding. The outstanding shares of common stock are validly issued, fully paid and nonassessable.

Holders of common stock are
entitled to one vote for each share on all matters presented to the stockholders. Holders of common stock do not have cumulative voting
rights. Therefore, holders of a plurality of the shares of common stock voting for the election of directors can elect all of the directors.
Holders of common stock representing 33.3 percent of our capital stock issued, outstanding and entitled to vote, represented in person
or by proxy, are necessary to constitute a quorum at any meeting of stockholders.

Holders of common stock are
entitled to